mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.6 |
mRNA |
BRD-K04800985 |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |
mRNA |
WZ3105 |
GDSC1000 |
pan-cancer |
AAC |
0.014 |
0.6 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.018 |
0.6 |
mRNA |
Vandetanib |
CCLE |
pan-cancer |
AAC |
-0.022 |
0.6 |
mRNA |
Bexarotene |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.6 |
mRNA |
BRD8899 |
CTRPv2 |
pan-cancer |
AAC |
0.018 |
0.6 |
mRNA |
regorafenib |
CTRPv2 |
pan-cancer |
AAC |
-0.018 |
0.6 |
mRNA |
BRD-K78574327 |
CTRPv2 |
pan-cancer |
AAC |
-0.035 |
0.6 |
mRNA |
CHIR-99021 |
CTRPv2 |
pan-cancer |
AAC |
0.016 |
0.6 |